Ruiz Briseno Andres 4

What Happened
Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at IDEAYA Biosciences (IDYA), was granted an 80,000-share derivative award on January 30, 2026 (reported as acquired at $0.00). The filing also shows two prior employee stock purchase plan (ESPP) acquisitions: 682 shares on 2024-11-29 at $23.26 ($15,861) and 1,253 shares on 2025-11-28 at $16.91 ($21,184). The large 80,000-item entry is a grant/award (not a sale) and is subject to vesting (see details below).

Key Details

• Primary transaction: 80,000 shares (derivative award) acquired 2026-01-30, reported price $0.00.
• Prior ESPP purchases: 682 shares @ $23.26 on 2024-11-29 ($15,861) and 1,253 shares @ $16.91 on 2025-11-28 ($21,184). Total ESPP shares = 1,935.
• Vesting: Footnote indicates 25% vests on the first anniversary measured from Jan 1, 2026 (Vesting Commencement Date); then 1/48th of total shares vest monthly so 100% vests on the fourth anniversary of that date.
• Footnote on ESPP: acquisitions were exempt under Rule 16b-3(d) and Rule 16b-3(c).
• Filing: Form 4 filed 2026-02-02 covering the 2026-01-30 grant — appears to be timely (filed within required business-day window).
• Shares owned after the transactions: not specified in this filing.

Context

• The 80,000-share item is a grant/derivative award (likely stock options or restricted stock units subject to the stated vesting schedule); reported $0.00 is typical for grants and does not mean an open-market purchase.
• ESPP purchases are routine employee purchases and are treated differently from open-market buys or insider sales; they are often exempt from short-swing profit rules per the cited Rule 16b-3 provisions.
• This filing reports acquisitions (not sales). Acquisitions can be seen as a positive signal but do not by themselves explain management intent; they are factual disclosures of insider holdings and grants.